Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2010 5
2011 11
2012 19
2013 25
2014 71
2015 102
2016 116
2017 142
2018 109
2019 96
2020 103
2021 80
2022 57
2023 49
2024 16

Text availability

Article attribute

Article type

Publication date

Search Results

877 results

Results by year

Filters applied: . Clear all
Page 1
CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies.
Castillo JJ, Furman M, Winer ES. Castillo JJ, et al. Expert Opin Investig Drugs. 2012 Jan;21(1):15-22. doi: 10.1517/13543784.2012.640318. Epub 2011 Nov 24. Expert Opin Investig Drugs. 2012. PMID: 22112004 Review.
EXPERT OPINION: CAL-101 is a novel drug that has shown preclinical activity against CLL, NHL, HL and PCM cells. There is early evidence of clinical efficacy in CLL and indolent NHL. Studies using CAL-101 alone or in combination are also ongoing in PCM, …
EXPERT OPINION: CAL-101 is a novel drug that has shown preclinical activity against CLL, NHL, HL and PCM cells. There is early …
Chronic lymphocytic leukaemia.
Hallek M, Shanafelt TD, Eichhorst B. Hallek M, et al. Lancet. 2018 Apr 14;391(10129):1524-1537. doi: 10.1016/S0140-6736(18)30422-7. Epub 2018 Feb 21. Lancet. 2018. PMID: 29477250 Review.
The impressive efficacy of kinase inhibitors ibrutinib and idelalisib and the BCL-2 antagonist venetoclax have changed the standard of care in specific subsets of patients. ...
The impressive efficacy of kinase inhibitors ibrutinib and idelalisib and the BCL-2 antagonist venetoclax have changed the standard o …
Idelalisib.
Zirlik K, Veelken H. Zirlik K, et al. Recent Results Cancer Res. 2018;212:243-264. doi: 10.1007/978-3-319-91439-8_12. Recent Results Cancer Res. 2018. PMID: 30069634 Review.
Idelalisib (GS-1101, CAL-101, Zydelig()) is an orally bioavailable, small-molecule inhibitor of the delta isoform (p110delta) of the enzyme phosphoinositide 3-kinase (PI3K). ...Idelalisib is the first PI3K inhibitor approved by the US Food and Drug Adm …
Idelalisib (GS-1101, CAL-101, Zydelig()) is an orally bioavailable, small-molecule inhibitor of the delta isoform (p110 …
Idelalisib.
[No authors listed] [No authors listed] 2018 Dec 3. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2018 Dec 3. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 29999908 Free Books & Documents. Review.
No information is available on the clinical use of idelalisib during breastfeeding. Because idelalisib is more than 84% bound to plasma proteins, the amount in milk is likely to be low. ...The manufacturer recommends that breastfeeding be discontinued during idel …
No information is available on the clinical use of idelalisib during breastfeeding. Because idelalisib is more than 84% bound …
Combining CAL-101 with Celecoxib Enhances Apoptosis of EBV-transformed B-Cells Through MAPK-induced ER Stress.
Park GB, Hur DY, Kim D. Park GB, et al. Anticancer Res. 2015 May;35(5):2699-708. Anticancer Res. 2015. PMID: 25964548
Co-treatment with CAL-101 and celecoxib triggered the ER stress response and the down-regulation of BCL2 and BCL-XL. ...Levels of apoptosis signal-regulating kinase 1 (ASK1) were also increased after treatment with CAL-101 and celecoxib. CONCLUSION: Th …
Co-treatment with CAL-101 and celecoxib triggered the ER stress response and the down-regulation of BCL2 and BCL-XL. ...Levels …
Idelalisib.
[No authors listed] [No authors listed] 2022 Jul 12. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2022 Jul 12. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31644147 Free Books & Documents. Review.
Idelalisib is an oral kinase inhibitor that is approved for use in combination with rituximab in relapsed or refractory chronic lymphocytic leukemia (CLL) and as monotherapy for relapsed follicular B cell, small lymphocytic lymphoma and indolent non-Hodgkin lymphoma. Id …
Idelalisib is an oral kinase inhibitor that is approved for use in combination with rituximab in relapsed or refractory chronic lymph …
ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Ghia P, Pluta A, Wach M, Lysak D, Kozak T, Simkovic M, Kaplan P, Kraychok I, Illes A, de la Serna J, Dolan S, Campbell P, Musuraca G, Jacob A, Avery E, Lee JH, Liang W, Patel P, Quah C, Jurczak W. Ghia P, et al. J Clin Oncol. 2020 Sep 1;38(25):2849-2861. doi: 10.1200/JCO.19.03355. Epub 2020 May 27. J Clin Oncol. 2020. PMID: 32459600 Clinical Trial.
Patients received acalabrutinib monotherapy or investigator's choice (idelalisib plus rituximab [I-R] or bendamustine plus rituximab [B-R]). ...
Patients received acalabrutinib monotherapy or investigator's choice (idelalisib plus rituximab [I-R] or bendamustine plus rituximab …
CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.
Lannutti BJ, Meadows SA, Herman SE, Kashishian A, Steiner B, Johnson AJ, Byrd JC, Tyner JW, Loriaux MM, Deininger M, Druker BJ, Puri KD, Ulrich RG, Giese NA. Lannutti BJ, et al. Blood. 2011 Jan 13;117(2):591-4. doi: 10.1182/blood-2010-03-275305. Epub 2010 Oct 19. Blood. 2011. PMID: 20959606 Free PMC article.
We thus identified 5-fluoro-3-phenyl-2-[(S)-1-(9H-purin-6-ylamino)-propyl]-3H-quinazolin-4-one (CAL-101), a highly selective and potent p110delta small molecule inhibitor (half-maximal effective concentration [EC(50)] = 8nM). ...These effects have been observed acro …
We thus identified 5-fluoro-3-phenyl-2-[(S)-1-(9H-purin-6-ylamino)-propyl]-3H-quinazolin-4-one (CAL-101), a highly selective a …
[CAL-101,a novel agent of targeted therapy in hematological malignancies].
Li CJ, Zhang Q, Zhang YZ. Li CJ, et al. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Apr;22(2):530-3. doi: 10.7534/j.issn.1009-2137.2014.02.049. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014. PMID: 24763037 Review. Chinese.
CAL-101 is a selective inhibitor of the phosphatidylinositol-3 kinase (PI3K), it inhibits the survival, proliferation and migration of tumor cells by directly inducing apoptosis and inhibiting micro-environmental interactions. ...This review focuses on the target, m …
CAL-101 is a selective inhibitor of the phosphatidylinositol-3 kinase (PI3K), it inhibits the survival, proliferation and migr …
Idelalisib.
[No authors listed] [No authors listed] Aust Prescr. 2016 Apr;39(2):60-2. doi: 10.18773/austprescr.2016.010. Epub 2015 Nov 19. Aust Prescr. 2016. PMID: 27340325 Free PMC article. Review. No abstract available.
877 results